intact animal to the cellular, subcellular, and molecular levels. It is published 12 times a year (monthly) by the American lymphatics, including experimental and theoretical studies of cardiovascular function at all levels of organization ranging from the publishes original investigations on the physiology of the heart, blood vessels, and AJP -Heart and Circulatory Physiology is thought to be the major cause of chronic heart dysfunction after myocardial infarction (MI). However, molecules involved in this process have not been thoroughly elucidated. In this study we investigated the long-term effects of the growth factor midkine (MK) in cardiac remodeling after MI. MI was produced by ligation of the left coronary artery. MK expression was progressively increased after MI in wild-type mice, and MK-deficient mice showed a higher mortality. Exogenous MK improved survival and ameliorated left ventricular dysfunction and fibrosis not only of MK-deficient mice but also of wild-type mice. Angiogenesis in the peri-infarct zone was also enhanced. These in vivo changes induced by exogenous MK were associated with the activation of phosphatidylinositol 3-kinase (PI3K)/Akt and MAPKs (ERK, p38) and the expression of syndecans in the left ventricular tissue. In vitro experiments using human umbilical vein endothelial cells confirmed the potent angiogenic action of MK via the PI3K/Akt pathway. These results suggest that MK prevents the cardiac remodeling after MI and improves the survival most likely through an enhancement of angiogenesis. MK application could be a new therapeutic strategy for the treatment of ischemic heart failure.
growth factor ISCHEMIC HEART DISEASE (IHD) remains a leading cause of morbidity and mortality in many industrialized countries. Current treatment options for patients with advanced IHD include medical therapy or coronary revascularization by percutaneous coronary angioplasty or coronary bypass graft surgery (33) . In a significant number of IHD patients, however, the standard revascularization therapies do not improve their clinical outcome. Induction of neovascularization by molecular biological procedures is expected to be a valid approach to ameliorate the pathophysiological changes in the ventricles of IHD. Transfer of angiogenic genes, cell implantation, and the administration of some growth factor proteins were reported to induce angiogenesis, leading to a prevention of cardiac fibrosis and resultant contractile dysfunction in animal IHD models (39) . Most double-blind placebo-controlled clinical trials to date, however, failed to demonstrate sufficient efficacy of these procedures (11, 34) .
Midkine (MK) is a heparin-binding growth factor with a molecular weight of 13 kDa, first isolated as the product of a retinoic acid-responsive gene in an embryonal carcinoma cell differentiation system, and is rich in basic amino acids and cysteine (15, 16) . Structurally, MK shares ϳ50% sequence homology with pleiotrophin/heparin-binding growth-associated molecule (PTN/HB-GAM) but is not related to other growth factors or neurotrophic factors. The mouse MK and human MK have more than 90% homology (23) , and human MK showed significant effects for mouse in vivo models (12, 13) . MK has various biological activities; it promotes neurite outgrowth, survival of embryonic neurons, fibrinolytic activity of endotheial cells, and the migration of inflammatory leukocytes. MK is expressed strongly in early as well as advanced stages of tumors and involved in carcinogenesis and tumor progression. MK could have an angiogenic action on the ischemic heart because MK was shown to increase vascular density in tumorigenesis (4) . The present study was designed to test this hypothesis in mouse models of myocardial infarction (MI). We have found that endogenous MK is responsible for adaptive angiogenesis in the heart after MI by regulating the activation of phosphatidylinositol 3-kinase (PI3K)/Akt and MAPKs. Exogenous application of MK was shown to improve cardiac function and survival of the post-MI mice through prevention of left ventricle (LV) remodeling. Notably, this improvement was observed not only in MK-deficient (MKKO) mice but also in wild-type (WT) mice.
MATERIALS AND METHODS
Mouse models. All animal experiments were performed in accordance with the regulations adopted by National Institutes of Health and approved by the Animal Care and Use Committee of Nagoya University. MKKO mice were generated as described elsewhere (25) . Adult male C57BL/6 (WT) and male MKKO mice with the C57BL/6 genetic background were used in either ischemic-reperfusion or a ligation model of MI (age, 10 -12 wk old; and weight, 22-25 g) and were fed normal rodent chow. Mice were anesthetized with pentobarbital (100 mg/kg ip) and ventilated through a nose cone with a tidal volume of 0.2 ml at 120 breaths/min using a rodent respirator (model SN-480-7; Shinano, Tokyo, Japan). The extremity leads of the ECGs were monitored continuously. A thoracotomy was performed in the left third intercostal space, and the beating heart was exposed. An 8-0 polypropylene suture was passed under the left coronary artery at the inferior edge of the left atrium and tied with a slipknot to produce occlusion. Myocardial ischemia was verified by blanching of the LV and ST elevation in ECGs. Air was then evacuated from the chest cavity, and the chest was closed with the ends of the slip outside of the incision. The ventilator was then removed, and normal respiration was restored. The blood samples of mice at 24 h after ischemic-reperfusion or the ligation procedure were collected from tail veins (0.2 ml each), and serum cardiac tropinin T (cTnT) levels were measured to estimate the initial MI size (SRL, Tokyo, Japan). The animals were euthanized 7-28 days after the surgical operation.
For the in vivo MK treatment experiments, MK protein in saline (1 mg/ml) was subcutaneously infused for 7-28 days by using an osmotic pump (Alza, Palo Alto, CA). As the control, saline was infused by the pump. The pumps were implanted under the abdominal skin and exchanged in each 7 days.
Histology. Mouse hearts were embedded in paraffin after fixation with 4% paraformaldehyde and were cut into 5-m sections across the apex-base axis of the LV.
To recognize structural remodeling after MI, the sections were stained by both hematoxylin and eosin and picrosirius red. The amounts of collagen deposition (scar area) were estimated from six cross sections to cover the whole ventricles in each heart using automated image analysis software (Scion, Frederick, MD). Ten high-power fields per sample were analyzed, and the results were totaled for each animal.
Immunohistochemistry. Immunostaining of MK in paraffin sections was performed as described previously (12) . Exposure to secondary antibody conjugated with goat anti-rat IgG (Jackson Laboratory, Bar Harbor, ME) was followed by incubation with biotinyl-tyramide and streptavidin-horseradish peroxidase (NEN Life Science Products, Boston, MA) to enhance the immunoreactive signals. The specificity of immunostaining for MK was confirmed by absorption of the anti-MK antibodies with recombinant MK, followed by heparin-sepharose affinity chromatography (12) .
Immunohistochemical studies of von Willebrand factor (vWF) and CD31 were used to detect newly developed microvessels. The frozen sections (5-m slices) were incubated overnight with the rat-anti-mouse vWF antibody (Santa Cruz, CA) or with the ratanti-mouse CD31 antibody (BD Biosciences, Franklin Lakes, NJ) then exposed to the secondary antibody conjugated with goat anti-rat IgG (BD Biosciences). The images were analyzed by two investigators who were blinded with respect to the identification of the groups. The results were expressed as average numbers of capillaries per square millimeter.
Echocardiography. Transthoracic echocardiography was performed with a Nemio 20 (Toshiba Medical, Tokyo, Japan) to evaluate global cardiac function before and after MI creation. Mice were lightly anesthetized with diethyl ether and placed in the supine position on a heating pad. The level of anesthesia was kept very light to maintain regular spontaneous respiration and to avoid compromising hemodynamic conditions (13) . A 12-MHz transducer was applied to the left hemithorax, and two-dimensional targeted Mmode tracings were recorded. The data were analyzed by an observer blinded to the treatment and genotype of mouse.
MK protein and antibodies. Human recombinant MK protein was generated and purified as previously described (12) . Monoclonal antibodies against mouse MK were raised by injection of the purified protein into rabbits and were refined by affinity chromatography on protein-A and MK columns. Antibodies were specific to MK and did not react with PTN/HB-GAM.
Culture of human umbilical vein endothelial cells. Human umbilical vein endothelial cells (HUVEC) were purchased (Iwaki, Tokyo, Japan) and maintained according to an attached manual. Briefly, recovery cells were cultured at 37°in 5% CO 2-20% O2 in 5% fetal bovine serum (FBS) supplemented with growth factors, 50 U/ml penicillin, and 50 g/ml streptomycin. HUVEC at the third or fourth passage were used for the in vitro Matrigel assay and for the Western blotting.
Western blot analysis. Western blot analysis was performed to evaluate protein levels. LV tissue homogenates were subjected to SDS-PAGE on a 7.5% polyacrylamide gel, and proteins were electroblotted on polyvinylidene fluoride (PVDF) membranes (Atto, Tokyo, Japan). After blocking, the membrane was incubated with primary antibodies: anti-mouse Akt/PKB antibody (Upstate, Lake Placid, NY) anti-diphosphorylated Akt/PKB antibody (Upstate), PI3K (Upstate), anti-moue ERK antibody (Sigma) anti-diphosphorylated ERK1/2 antibody (NEN Life Science Products), hypoxia inducible factor (HIF)-1␣ (Bethyle, Montgomery, TX), JNK (Cell Signaling Technology, Boston, MA), P38 (Cell Signaling Technology), Bcl-2, Bad, and Bax (Santa Cruz Biotechnology, Santa Cruz, CA) and then exposed to biotinylated anti-mouse IgG (Sigma, St. Louis, MO), horseradish peroxidase-conjugated streptavidin (Amersham Pharmacia Biotech, Little Calfont, UK), and enhanced chemiluminescence reagent (Amersham Pharmacia Biotech).
To detect Akt and ERK1/2 proteins in vitro, cultured HUVEC were lysed in SDS sample buffer, the cell lysate was subjected to SDS-PAGE on a 7.5% polyacrylamide gel, and proteins were etectroblotted on PVDF membrane. The membrane was sequentially immunoblotted as described above. The intensity of the bands was quantified by densitometry (Atto).
Matrigel angiogenesis assays. For in vitro assay, the maintaining medium of confluent HUVEC was changed into 0.5% FBS in endothelial cell basal medium (EBM)-2 without supplemented growth factors. Twenty-four hours later, the medium was then aspirated and the cells were washed twice with phosphate-buffered saline (PBS), trypsinized, and plated in wells coated with growth factor-depleted Matrigel (Becton Dickison, Bedford, MA) (18) in 0.5% FBS in EBM-2 without growth factors. The HUVEC were then treated with either 100 ng/ml MK, 100 ng/ml basic FGF (bFGF; positive control), or PBS (control). At 6 h later, the palates were photographed, and the extent of tube formation was qualitatively assessed.
To assess the angiogenic efficacy in vivo, C57/BL6 mice were anesthetized with pentobarbital (100 mg/kg ip injection). The growth factor-depleted Matrigel was mixed with 20 U/ml heparin (Elkins Sinn, Cherry Hill, NJ) and either 500 ng/ml MK, 500 ng/ml bFGF (positive control), or PBS (control). Matrigel mixture (0.5 ml) was injected subcutaneously in the abdominal midline using sterile conditions. Fourteen days later, the pellets were then collected with a piece of underlying abdominal wall, fixed with paraformaldehyde for 2 h, and processed for paraffin embedding. The sections cut into 5 m thickness were stained with hematoxylin and eosin or immunostained with an antibody against vWF. Images of sections at ϫ40 magnification were photographed with a digital camera and analyzed using automated image analysis software. Ten random high-power fields were analyzed, and the results were totaled for each animal.
Real-time PCR. To quantify mRNA expression of Syndecans (Assay ID: Sdc1 Mm00448918_m1, Sdc3 Mm01179832_m1, Sdc4 Mm00488527_m1), PI3K catalytic subunit p110 (Mm00440894_m1), Akt, monocyte chemoattractant protein (MCP)-1 (Ccl2 Mm00441242_m1), matrix metalloproteinases (MMP)-2(Mm00439508_m1) and MMP-9(Mm00600163_m1) in the LV free wall of mouse hearts and HUVEC, we performed a real-time PCR assay (Perkin-Elmer ABI Prism 7700) (27) . 18s mRNA was used as an internal control. Sequence-specific probes were purchased from Applied Biosystems (Foster City, CA).
Statistic analysis. All values are expressed as means Ϯ SE. Statistical comparisons among the groups were performed by ANOVA with Bonferroni post hoc tests. Comparisons between two groups were made using unpaired Student's t-test. The cumulative survival rate of mice after MI creation was analyzed by Kaplan-Meier method with the long-rank procedure. Probability values of Ͻ0.05 were considered significant.
RESULTS

MK expression pattern in chronic phase.
We evaluated the time course of MK expression after MI. The protein expression gradually increased, became apparent at 7 days, and persisted until 14 days (Fig. 1A, top) . mRNA expression levels of MK were elevated from 3 days (4.0-fold; P Ͻ 0.05 vs. sham) to 14 days (7.2-fold; P Ͻ 0.05 vs. sham; Fig. 1A,  bottom) .
Survival rate after MI is improved by exogenous MK treatment. In MKKO mice, most animals (7 of 8) died by 7 days after MI, whereas the survival rate of WT mice was 44% at 28 days [WT with no treatment (WT-NT) in Fig. 1B] . Pump failure or ventricular rupture occurred more frequently in MKKO (5 of 7) than in WT (3 of 10) mice.
To examine the therapeutic potential of MK treatment after MI, we subcutaneously administered MK protein using an osmotic pump to MKKO mice. The survival rate of MKKO mice was significantly improved by supplemental treatment of MK protein [knockout (KO)-MK in Fig. 1B ]. We further examined the effect of MK treatment on WT mice. At 24 h after MI, there was no significant difference of the serum cTnT level between WT-NT and MK treatment (WT-MK) groups (data not shown). Surprisingly, the survival rate was significantly improved to 90% by MK (P Ͻ 0.05; WT-MK in Fig. 1B) . Consistent with this phenomenon, the serum brain natriuretic peptide (BNP) level at 28 days after MI in WT-MK mice was significantly lower than that of WT-NT (129 Ϯ 5 pg/dl vs. 370 Ϯ 98 pg/dl; P Ͻ 0.05; Fig. 1C ).
MK treatment suppressed cardiac dysfunction and prevented progression of heart failure after MI. Figure 1D summarizes the parameters of echocardiography 7-28 days after MI. Without MK treatment (WT-NT), LV end-diastolic diameter (LVEDd) and LV end-systolic diameter (LVESd) were progressively increased, whereas ejection fraction (EF) and fractional shortening (FS) were progressively decreased during the entire follow-up period. This deterioration was prevented by MK treatment (WT-MK). LVEDd and LVESd at 28 days in WT-MK (4.3 Ϯ 0.5 mm and 3.6 Ϯ 1.0 mm) were significantly smaller than those in WT-NT (6.0 Ϯ 0.4 mm and 5.3 Ϯ 0.4 mm; P Ͻ 0.05). EF and FS at 28 days in WT-MK (44.3 Ϯ 10.1% and 21.2 Ϯ 5.4%) were significantly better than those in WT-NT (32.1 Ϯ 0.6% and 15.3 Ϯ 0.3%; P Ͻ 0.05).
Exogenous MK treatment inhibits LV remodeling and enhances neovascularization in WT mice after MI. To estimate LV remodeling, we first examined fibrosis. The area of collagen deposition quantified by picrosirius red staining at 28 days after MI in WT-MK was significantly smaller than that in WT-NT ( Fig. 2A) . Incidence of collagen deposition in WT-NT was expanded not only in the infarct zone but also in noninfarcted remote myocardium ( Fig. 2A) .
We next examined the gene expression of MMPs in the LV tissue. The MMP-9 mRNA level at 28 days after MI was significantly lower in WT-MK than in WT-NT (5.4 Ϯ 1.82 vs. 2.2 Ϯ 0.87; P Ͻ 0.05; Fig. 2B ). The MMP-2 mRNA level at 28 days after MI in WT-MK tended to be lower than that in WT-NT although the difference did not reach a statistical significance (Fig. 2B) .
Neovascularization was evaluated by means of immunohistochemistry. The CD31-immunopositive microvessel popula- Fig. 3, A and B) . To analyze the association between angiogenic phenomenon in WT-MK and proinflammatory action, we assessed transcript levels of MCP-1 in mouse LV tissue 7 days after MI. The expressions of MCP-1 mRNA in WT-MK were significantly higher than in WT-NT (1.35 Ϯ .45 vs. 0.6 Ϯ .17; P Ͻ 0.05; Fig. 3C ).
To guarantee the above-mentioned protective effect of exogenous MK administration, administered MK must be properly delivered to the injured site of the heart. Figure 3D shows the localization of MK protein administered via an osmotic pump in a KO-MK mouse. The infused MK protein was localized in residual cardiomyocytes in the peri-infarct zone, and the MK accumulation area was roughly consistent with the CD31-enriched area.
Exogenous MK treatment enhances PI3K/Akt and MAPK signaling. Enhanced neovascularization by MK treatment prompted us to examine the expression of cell surface molecules (syndecans) and intracellular ones (PI3K, Akt, ERK, p38, and HIF-1␣) that have relation to angiogenesis. (Fig. 4) .
Although there were no substantial differences of expressions of total PI3K and Akt between WT-MK and WT-NT, phosphorylation of PI3K (p-PI3K) and p-Akt was significantly increased in WT-MK (by 76.2% and 61.3%, respectively; P Ͻ 0.05) compared with WT-NT (Fig. 5A) . Akt phosphorylation was remarkably reduced in the MKKO compared with WT at 24 h after MI (0.23 Ϯ 0.09 vs. 0.9 Ϯ 0.29; P Ͻ 0.05; Fig. 5A ). p-Akt was localized in the microvessel area in WT-MK (Fig.  5B) . The expression of p-ERK1/2 and p-p38 in WT-MK were significantly higher than in WT-NT (p-ERK1/2, 1.48 Ϯ 0.75 vs. 0.57 Ϯ 0.18; p-p38MAP, 1.98 Ϯ 0.44 vs. 0.21 Ϯ 0.054; P Ͻ 0.05; Fig. 5C ).
Expression of the transcription factor HIF-1␣ was also examined. HIF-1␣ expression was remarkably increased in WT-MK (0.085 Ϯ 0.041 vs. 0.028 Ϯ 0.013; P Ͻ 0.05; Fig. 5D ).
Exogenous MK treatment reduced apoptosis. The cellular consequence after MK administration was further evaluated as * * (Fig. 6A) . The bax-to-bcl-2 expression ratio of the LV tissue in WT-MK was significantly suppressed compared with that of WT-NT (0.72 Ϯ 0.37 vs. 1.46 Ϯ 0.32; P Ͻ 0.05; Fig.  6B ). p-Bad was significantly increased in WT-MK compared with WT-NT (1.0 Ϯ 0.2 vs. 1.2 Ϯ 0.2; P Ͻ 0.05; Fig. 6C ).
Angiogenic activity of MK in Matrigel assay in vitro and in vivo.
To confirm the ability of MK to enhance angiogenesis, we first examined the effect of exogenous MK on the formation of vascular structure of HUVEC in an in vitro Matrigel assay. Treatment of HUVEC with 100 ng/ml MK for 6 h resulted in a considerable acceleration of the formation of visible rings and cords of cells on growth factor-depleted Matrigel in the absence of serum. This enhancement of tubular network formation by MK was comparable with the effect of 100 ng/ml bFGF (Fig. 7A) . We also examined the effect of MK on the activation of Akt in HUVEC by Western blotting (Fig. 7B) . Treatment of HUVEC with 100 ng/ml MK for 6 h caused a significant increase of p-Akt (by 68.2% from control; P Ͻ 0.05), and this upregulation was reversed completely by the concomitant application of 30 nmol/l wortmannin, a specific inhibitor of PI3K. The network formation of HUVEC enhanced by MK was reversed by wortmannin (Fig. 7A) .
To assess the angiogenic properties of MK in vivo, we measured the extent of vessel invasion into Matrigel pellets implanted in mouse abdominal walls. The incorporation of 500 ng/ml MK into the Matrigel resulted in a significant increase of vessels seen after 14 days compared with that of control pellets. The increase of capillary density by MK, which was measured by immunostaining for vWF in the pellets, was comparable with the effect of 100 ng/ml bFGF (Fig. 7, C  and D) .
DISCUSSION
The present study demonstrated that MK plays a crucial role in the cardiac remodeling after MI. Exogenous in vivo application of MK to WT mice after MI activated PI3K/Akt and MAPKs. Concomitantly, exogenous MK enhanced neovascularization in the peri-infarct zone, ameliorated LV fibrosis and dysfunction, and improved survival rate. Moreover, MKKO mice showed a higher mortality and less activation of Akt compared with WT mice. The angiogenic action of MK, which was associated with Akt activation, was confirmed in in vitro experiments using HUVEC. Taken together, these results suggest that MK exerts a protective effect against the ventricular remodeling after MI through the activation of angiogenesis.
Angiogenesis is the most important repair process of tissues subjected to ischemic insult, and stimulation of neovascularization is expected to reduce ventricular remodeling and dysfunction after MI (17, 36) . The intracellular signaling molecules responsible for the neovascularization include PI3K/Akt and MAPKs (13, 24, 28) . Among them, Akt is a serine/threonine protein kinase that is activated by a number of growth factors (e.g., VEGF, hepatocyte growth factor, and bFGF) in a PI3K-dependent manner. Akt regulates multiple critical steps in angiogenesis, including endothelial cell survival, migration, and capillary-like structure formation (32) . HIF-1␣ exists downstream of Akt and regulates expression of many angiogenesis-related genes including those of VEGF and FLT (2, 9, 18, 20) . It is of note that HIF-1␣ upregulates MK expression (30) . Therefore, the potent angiogenic activity of MK as shown in the present experiments using mouse MI models would be explained primarily by the PI3K-Akt signaling axis like other growth factors. The marked reduction of Akt phosphorylation in MKKO mice suggested that MK has critical role to activate Akt, and indeed, exogenous treatment of MK for WT mice caused remarkable acceleration of Akt and PI3K activation after MI. In addition to these in vivo data, the in vitro action of exogenous MK on HUVEC to activate Akt and promote tubulogenesis was prevented by wortamannin, a specific inhibitor of PI3K.
Angiogenesis is deeply associated with inflammatory reaction (1). For instance, monocyte/macrophages accumulation is a critical player in both capillary sprouting and collateral artery growth. These inflammatory cells produce a variety of angiogenic cytokines and growth factors upon activation. MCP-1, TNF-␣, bFGF, and MMPs belong to their repertoire (14, 37) . In this study, the expression pattern of MK matched with the macrophage infiltration in acute or subacute inflammation phase after MI (14) , and the survival rate of MKKO mice was significantly worse than WT in this phase (Fig. 1) . From these data, there is a possibility that MK is also produced by inflammatory cells. In fact, Narita et al. (26) showed that MK is expressed by macrophages in neointima of hypercholesterolemic rabbits. On the other hand, MK is known to promote the chemotaxis of neutrophils or the migration of macrophages (12) . Our laboratory has shown previously that MK has a critical role in neointima formation by enhancing the recruitment of inflammatory cells (12) . MK also induces activation of MCP-1 and mediates the inflammatory reaction in the kidney subjected to ischemia-reperfusion (31). These observations suggest that the potent angiogenic activity of MK in the heart after MI is mediated in part by its proinflammatory action.
Is associated with an inflammatory reaction, which is a prerequisite for healing and scar formation. There is complex interplay among many factors involved in the reaction. In terms of LV remodeling and dysfunction after MI, inflammation can induce either undesirable or beneficial effects (10, 14) . The former effect is the result of the progression of myocardial injury, whereas the latter one is the result mainly of an enhancement of angiogenesis, and the final consequence is determined by their balance under a variety of pathological conditions (7) . Among MK-associated inflammatory molecules, MCP-1 has long been considered to play a deleterious role in postinfarct LV dysfunction and remodeling. Morimoto et al. (21), however, have shown in their study using transgenic mice that the cardioselective overexpression of MCP-1 prevents LV dysfunction and remodeling after MI through an enhancement of neovascularization.
We also found in the present study that the expression of syndecans was enhanced in MK-treated WT mice. Syndecans are membrane-bound heparan sulfated proteoglycans, and implicated in angiogenesis. For example, mice lacking Synd-4 show impaired angiogenesis, and Synd-2 is required for angiogenic spouting during zebrafish development (3, 6) . It is interesting that MK binds to syndecans (6) . Furthermore, a recent study by Vanhoutte et al. (35) using mice of targeted Synd1 deletion and adenovirus Synd1 gene overexpression has demonstrated that increased the expression of Synd-1 in MI prevents inverse healing, thereby reducing cardiac dilatation and dysfunction after MI. Accordingly, MK-induced syndecan family could contribute the amelioration of LV remodeling and dysfunction after MI through a similar mechanism. Beside syndecans, MK binds to other cell surface molecules. The MK receptor is thought to be a molecular complex including syndecan family members; protein-tyrosine phosphatase-, a chondroitin sulfate proteoglycan; members of the low density lipoprotein receptorrelated protein family; and anaplastic lymphoma kinase, a receptor-type tyrosine kinase (15, 19, 22, 24) . Biological significance of these molecules after MI remains to be verified.
Fukui et al. (8) recently showed that MK has therapeutic effects for cardiac remodeling after MI. Although they did not show the detailed molecular mechanisms, the results were similar with our data in the point that the angiogenic effect of MK showed preventive action for LV remodeling. In addition to their data, we have shown the involvement of the PI3K/Akt pathway in MK-mediated angiogenesis. Furthermore, the antiapoptotic effects of MK in MI model were demonstrated in the present study. We previously showed in mouse acute MI model induced by ischemia-reperfusion that MK ameliorates acute myocardial injury through its potent antiapoptoic action (13) . In this study, we also found that MK treatment reduced apoptotic reaction in the chronic phase of ligation model. The signaling pathways of angiogenesis and apoptosis overlap and cross-talk each other: MAPKs especially initiate the activation of Bax and Bcl-2 (29) . Bad, an proapoptotic member of the Bcl-2 family, is displaced by Bax from binding to Bcl-2 and Bcl-XL (38) . In addition to MAPKs, the phosphorylated Akt inhibits the apoptotic effects of Bad (5). These facts suggest that the MK could prevent remaining myocardiocytes from apoptosis via MAPKs and Akt pathways. The potent angiogenic and antiapoptotic activities of MK in the chronic phase of MI may synergistically exert effects on the prevention of LV remodeling and dysfunction in favor of long-term survival. The beneficial effects of exogenous MK application would provide a new perspective for the innovation in the treatment of MI.
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